In October , he started as a clinical resident at the General Surgery department of the Sint Lucas Andreas Hospital, as the first part of the six-year trajectory to become an Orthopaerdic Surgeon. Pieter has implemented photodynamic therapy using the new photosensitizer Bremachlorin and using photodynamic therapy to enhance the effect of therapeutic tumor vaccination. Fluorescence guided surgical oncology In cancer surgery, intra-operative assessment of the tumor-free margin, which is critical for the prognosis of the patient, relies on the visual appearance and palpation of the tumor.
Optical imaging techniques provide realtime visualization of the tumor, warranting intra-operative image-guided surgery. Within this field, imaging in the near-infrared light spectrum offers two essential advantages: increased tissue penetration of light and an increased signal-to-background-ratio of contrast agents. The major challenges lie in the development, validation and clinical introduction of a tumor specific agent and the development and introduction of a NIR fluorescence camera. Furthermore, the Artemis camera was characterized and evaluated pre clinically figure.
Fluorescence guided, targeted photodynamic therapy Even with a highly specific targeting agent available, the fundamental problems associated with detecting weak fluorescence signals may sometimes prevent identification of the tumor border by fluorescence.
Scientic Report by Erasmus MC - Dept. of Radiology & Nuclear Medicine - Issuu
Post-operative targeted photodynamic therapy could eradicate the small invasive tumor strands not detected by fluorescence imaging. This project focuses on nanobody based EGFR targeted photodynamic therapy. Pieter is now in training as an orthopedic oncological surgeon in LUMC and has finished his thesis which he defended 24th of October in Internal Medicine. In , the Depts.
Scientific interests include preclinical and translational molecular multimodality imaging and radionuclide therapy. Bakker, I. Haeck, G. Doeswijk, E. Segbers, T. Maina, B. Nock, M. Dalm, Mol Imaging Biol, Such tracers labeled with beta- or alpha-particle emitters can also eradicate target-expressing tumors and other diseases. Meester, E.
Krenning, R. Norenberg, M. Bernsen, and K. Van der Heiden, J Nucl Cardiol, Westerlund, K. Altai, B. Mitran, M. Konijnenberg, M. Oroujeni, C. Atterby, M. Orlova, J. Mattsson, P. Micke, A. Karlstrom, and V. Tolmachev, J Nucl Med, In the clinic, convincing beneficial PRRT effects in terms of objective tumor response, increase of progression free survival and improvement of quality of life in comparison with conventional treatment have been reached.
Yet, complete responses are rare, therefore an improvement of the tumor response rate is highly warranted and currently several options are under investigation at the preclinical level between brackets the names of the team members working on these projects. Moreover, somatostatin analogues appear promising analogs for imaging of vulnerable plaques and macrophages. Danny Feijtel]. Therapeutic studies form an important part of our research, both using beta and alpha particle emitters, coupled to different tracers or particles.
We both aim at improving anti-tumor effects and at decreasing normal organ toxicity to enhance the therapeutic window of such tracers, including the application of pretargeting approaches. We also participate in a collaborative project on necrosis-directed imaging and therapy. We will continue our longstanding and fruitful collaborations with partners providing the required additional expertise most importantly with research groups in the AMIE facility at the Erasmus MC, in the Medical Delta with Delft and Leiden University, in Nijmegen, in Athens, in Montpellier, in the US and with multiple industry partners.
Stabilization of easily degradable compounds has shown to be essential in certain cases; we developed a novel method to stabilize compounds by in vivo inhibition of degradation using enzyme inhibitors. Maina-Nock and Dr. Funding Leo Hofland, Marion de Jong. Erasmus MC grant Epigenetic therapy to increase efficacy and optimize patient outcome of peptide receptor radionuclide therapy. Marion de Jong. Stichting Voorvechter Donation for Cancer Research.
Dutch Cancer Foundation Grant: This research line is performed with Monique Bernsen and Joost Haeck. Jong, Marion de. Monique Bernsen. Mediso Inc. Research grant. We aim to introduce several new and exciting tracers mostly radiopeptides into the clinic for imaging and radionuclide therapy of e. Jong, Marion de, and Harrie Weinans Orthopedics. Preclinical and clinical molecular imaging will continue to play an important role in the preclinical evaluation of these radiotracers as well as in the back translational studies that we perform to bring new compounds and techniques in to the clinic as well as to improve current compounds and techniques already clinically applied.
We will expand our work on combination therapies, including. Osch, Gerjo van Orthopedics and Monique Bernsen. Jong, Marion, de and Julie Nonnekens. Commercial collaboration Advanced Accelerator Applications First European workshop for alpha and beta radiopharmaceuticals, Munich, Germany. February Sept Preclinical Neobomb applications several projects. Simone Dalm. Julie Nonnekens. Feb Oct Speakertour Dr. Gerhardt Attard, Rotterdam. Erasmus University Rotterdam fellowship.
- Ethiopia says its troops marching on Tigrayan capital.
- best gay apps Schelle Belgium.
- bdsm gay escort Ans Belgium!
- straight fuck gay Saint Ghislain Belgium.
- YC Models joined Dominique Models!
- 50+ Mood i love ideas | tim walker photography, fashion photography, fashion design for kids.
- best gay dating app Maasmechelen Belgium;
This patent has been granted in Hillary Barrett. One of the researchers on the project met the CBR team after the finish and was handed symbolically the euro cheque. This DyMIC Dutch young Molecular Imaging Community aims to: lower the barriers into the imaging field for young researchers; increase the visibility of the Dutch imaging community; and increase collaborations between groups via networking between young researchers.
I developed imaging protocols for a radionuclide that is relatively new in imaging and therapy, bismuth, and made the first high resolution images using this radionuclide. I provide imaging expertise to researchers within our research group and to external collaborators. My tasks include the daily laboratory affairs and the supervision of trainees and students.
In general I provide support in cell culturing, cell labeling, animal handling, surgical procedures in animals, and histological tissue analysis. Furthermore, I have been involved in various other collaborative research projects in and outside the Erasmus MC.
Nicole van Vliet, BSc, Research Technician I am a research technician specialized in molecular biology and experimental animal work. We also perform experiments to better understand the off-target effects in kidneys and salivary glands. May - Feb Dec June Daily supervisor Eline Ruigrok. In , she joined the Erasmus MC Dept.
This research line comprises both basic research and translational research. This includes quantitative MR imaging approaches based on T1 and T2 mapping techniques for which groundwork was established in research projects focused on cell tracking. Main Research Topics Monitoring and predicting response to cancer therapy In assessing and improving the efficacy of novel anti-cancer treatment strategies, efficient drug delivery, response monitoring, and patient selection are important issues.
It is becoming increasingly clear that treatment efficacy is not only dependent on the tumor cell itself, but also on tumor micro-environment characteristics. Within this research line, imaging tools for the assessment of tumor micro-environment characteristics and early response parameters are being developed and validated. Within these projects multimodality imaging approaches play a central role. By combining the information obtainable from different imaging modalities, drug delivery and bio-distribution can be studied in relation to local tissue characteristics.
Within this research line there are various funded projects focused on the use of imaging techniques aimed at improved diagnosis, characterization, and treatment monitoring of disease mainly cancer, cardiovascular disease and osteoarthosis. A subline focuses on methods for in vivo cell tracking to monitor the fate of cellular grafts cell-based therapy. The majority of the projects require. More detailed information of the various projects can be found in the project descriptions of the PhD students and post-docs.
Through the use of molecular imaging and high resolution functional imaging, we address the scientific and clinical demand for more specific assessment of pathobiological processes in order to better understand, diagnose, monitor, and treat diseases and disease processes.
Order confirmation
Successful implementation of such imaging techniques requires a multi-disciplinary approach. Therefore we will further strengthen and expand collaborations with partners providing the required additional expertise. In return, through the developed techniques within current and future research projects and our close involvement in the Applied Molecular Imaging Erasmus MC AMIE program and the integrated imaging facility, we can provide imaging expertise with a range of state-of-theart pre-clinical modalities to other groups strengthening their research.
In vivo cell imaging Cell imaging is of crucial importance in studies where the role of a specific cell population, whether of endogenous or exogenous origin, is of specific interest. This includes projects aimed at monitoring the fate of transplanted stem cells in selected regenerative medicine approaches see projects Maarten Leijs and Sohrab Khatab, or the role of endogenous macrophages in specific disease processes see projects Sandra van Tiel and Eric Meester. However, in specific situations we also use optical imaging techniques and ultrasound-based imaging.
In the past period we have collaborated with various departments in assessing the possibilities and potential added value of imaging techniques within their research. These include: MR thermometry applications in a preclinical setting, MRI of plaque composition in human- and porcine-model-derived carotid plaques tissue specimen and high resolution PET imaging of human tissue samples. Principle of using ultrasound bubbles for targeted labeling of cells with SPIO.
Mark performed his PhD research in experimental nuclear physics research on neutron capture reactions of hydrogen and deuterium nuclei at the High Flux Reactor in Petten, NL. Patients were treated with a neutron beam, which induced alpha-particles by capture reactions with a 10B atom-rich drug that targeted to brain tumors glioma. After working several years with a radiopharmaceutical drug company Mallinckrodt in the research of therapeutic radionuclides and their radiation dosimetry, Mark switched over to Erasmus MC in He continued his research in absorbed dose assessments and dose-effect relations for molecular radiotherapy.
Currently Mark is chair of the EANM dosimetry committee and involved in writing several guidance documents for applying dosimetry within nuclear medicine therapeutic applications. The main task of the dosimetry committee currently is to give guidance in methods to perform dosimetry guided treatment planning for nuclear medicine therapy in accordance with the basic safety standards legislation.
Radiation-induced toxicities are however seldom observed in the current setting of radionuclide therapies like peptide receptor radionuclide therapy PRRT with Lu-DOTA-octreotate for the treatment of metastasized neuroendocrine tumours. Therapies are now administered in empirically determined fixed activity cycles with minimal adjustment according to clinical status, like compromised bone marrow reserve or renal impairment.
Despite the clinical success of PRRT already its value can be increased by tailoring the therapy to the patient-specific needs for cure. In the newly developed therapies dosimetry forms a valuable instrument to get an impression of its safety and therapeutic efficacy.
Influencers
Within the EANM dosimetry committee we tried to get this directive in the picture of the nuclear medicine community and give advice on how to perform dosimetry assessments. This has led to numerous discussions as many nuclear medicine clinicians are not convinced of introducing patient-specificity into the therapies they offer their patients. In the development of new radionuclide therapies treatment planning and dosimetry should be an essential part of its introductory plan. Acute radiation toxicity can be most of the times managed by good clinical follow-up, but late-occurring toxicity may be overlooked by confounding influences from the disease itself or by adverse events from other therapies.